Mutations in the DNA encoding for isocitrate dehydrogenases (IDH) mutations are recognized as one of the main molecular markers in 70–80% of stage II or III astrocytomas, oligodendrogliomas, and secondary GBMs, as opposed to primary tumors1. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).